• Rebecca Liang from Bernstein sets a price target of $207 for BeiGene, Ltd. (NASDAQ:BGNE), indicating a minor difference from its current price.
• The European Commission's approval of TEVIMBRA marks a significant milestone, allowing its use in advanced esophageal and gastric cancer treatments.
• Analysts project BeiGene's revenues to reach $4.64 billion next year, with a 12-month price target of $293 per share, indicating strong buy recommendations.

BeiGene, Ltd. (NASDAQ:BGNE) is a global biotechnology company focused on developing innovative cancer treatments. It is listed on NASDAQ, HKEX, and SSE. Recently, Rebecca Liang from Bernstein set a price target of $207 for BeiGene, which was slightly below the stock's price of $207.825 at the time, indicating a minor difference of -0.40%.

The recent approval of BeiGene's drug, TEVIMBRA, by the European Commission marks a significant milestone for the company. This approval allows TEVIMBRA to be used in combination with chemotherapy for treating advanced esophageal and gastric cancers. The drug's entry into the European Union market follows its introduction in the US in October, as highlighted by the European Commission.

TEVIMBRA's approval, along with the performance of another drug, BRUKINSA, is expected to boost BeiGene's revenue per share. Analysts project revenues to reach $4.64 billion next year, potentially driving the company towards profitability within 12 to 18 months. This optimistic financial outlook has led to a 12-month price target of $293 per share, indicating strong buy recommendations.

The stock is currently priced at $215, reflecting a 4.29% increase with a price change of $8.84. It has fluctuated between $211.37 and $216.37 during the trading day. Over the past year, the stock has seen a high of $248.16 and a low of $126.97. BeiGene's market capitalization is approximately $22 billion, with a trading volume of 258,492 shares.